About the Company
aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on aTYR PHARMA INC
ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations
Tyr Pharma, Inc. (NASDAQ:ATYR) is one of the top multibagger penny stocks to buy, according to analysts. On August 4, ...
aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional ...
If you want to know who really controls aTyr Pharma, Inc. (NASDAQ:ATYR), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company ...
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash ...
aTyr Pharma Inc (NASDAQ:ATYR) is competing in a market with large pharmaceutical players, which could pose challenges in terms of market penetration and competition.
24,423 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Farther ...
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1.
aTyr Pharma Reports Q2 2025 Financial Results
Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.
aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and welcome to the aTyr Pharma fourth quarter and full year 2023 conference call. At this time, all participants are in a listen only mode.
Is aTyr Pharma, Inc. (ATYR) the Low Risk High Reward Stock Set to ...
In 2024, aTyr Pharma, Inc. (NASDAQ:ATYR) spent $54.4 million on R&D, consisting mostly of these trials and manufacturing efzofitimod.
aTyr Pharma to Present New Data on the Mechanism of Action of ...
aTyr Pharma to Present New Data on the Mechanism of Action of Efzofitimod at the American Thoracic Society 2023 International Conference Jan. 31, 2023 8:00 AM ET aTyr Pharma, Inc. (ATYR) ...
If You Had Bought aTyr Pharma's (NASDAQ:LIFE) Shares Five Years Ago You ...
While not a mind-blowing move, it is good to see that the aTyr Pharma, Inc. (NASDAQ:LIFE) share price has gained 17% in the last three months.
aTyr Pharma Inc (NASDAQ:ATYR) - Shares, Dividends & News - Intelligent ...
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its ...
Here's What aTyr Pharma, Inc.'s (NASDAQ:LIFE) Shareholder Ownership ...
Hedge funds don't have many shares in aTyr Pharma. Looking at our data, we can see that the largest shareholder is Federated Hermes, Inc. with 19% of shares outstanding.
Similar Companies
Loading the latest forecasts...